Publications

November 12, 2022

Discovery of remyelination therapeutics that overcome the effects of inflammatory macrophages on oligodendrocyte formation

Kym I Lorrain, Michael M Poon, Alexander Broadhead, Geraldine Edu, Jonah R Chan, Austin Chen, Daniel S Lorrain

Presented at Neuroscience 2022

November 12, 2022

PIPE-791, a potent brain-penetrant selective LPA1 antagonist, reduces neuroinflammation in vivo

Geraldine C Edu, Michael M Poon, Ariana O Lorenzana, Alexander Broadhead, Chris Baccei, Jeff Roppe, Thomas Schrader, Lino Valdez, Yifeng Xiong, Austin Chen, and Daniel S Lorrain

Presented at Neuroscience 2022

Characterization of M1 Selective and Brain Penetrant [11 C] PIPE 307 PET Radiotracer in Cynomolgus Monkeys

Austin Chen, Amy Llopis Amenta, Chris Baccei, Giulia Boscutti, Benjamin P. Burke, Christophe Plisson, Christine Sandiego, Lisa Wells, Daniel Lorrain

Presented at Brain & Brain PET 2022

November 8, 2021

Lysolecithin (LPC) induced demyelination of the optic chiasm as a model to evaluate remyelinating agents

Geraldine C Edu, Ariana O Lorenzana, Michael M Poon, and Daniel S Lorrain

Presented at Neuroscience 2021

November 8, 2021

PIPE-307, a brain penetrant M1 selective antagonist, exhibits scopolamine-like antidepressive effects

Michael M Poon, Alexander Broadhead, Karin J Stebbins, Jeff R Ropp2, Jill Baccei, Austin C Chen, Daniel S Lorrain

Presented at Neuroscience 2021

November 8, 2021

Discovery of a Novel M1 Selective Antagonist, PIPE-307, for the Treatment of Multiple Sclerosis

Kym I Lorrain, Michael M Poon, Alexander Broadhead, Karin J Stebbins, Austin Chen, Jill Baccei, Ari J Green, Jonah R Chan, Daniel S Lorrain

Presented at Neuroscience 2021

December 24, 2020

Discovery of PIPE-359, a Brain-Penetrant, Selective M1 Receptor Antagonist with Robust Efficacy in Murine MOG-EAE

Thomas O. Schrader, Yifeng Xiong, Ariana O. Lorenzana, Alexander Broadhead, Karin J. Stebbins, Michael M. Poon, Christopher Baccei, and Daniel S. Lorrain

ACS Medicinal Chemistry Letters

October 19, 2019

PIPE-359, a novel, potent and selective M1 muscarinic receptor antagonist as a therapeutic approach for remyelination in multiple sclerosis

Karin J Stebbins, Michael M Poon, Alexander Broadhead, Geraldine Edu, Ariana Lorenzana, Kym I Lorrain, Thomas Schrader, Yifeng Xiong, Jill Baccei, Christopher Baccei, Ari J Green

Presented at Neuroscience 2019

October 19, 2019

Small molecule inhibition of the muscarinic M1 acetylcholine receptor by potent, selective antagonists facilitate OPC differentiation

Michael M Poon, Kym I Lorrain, Ariana O Lorenzana, Karin J Stebbins, Alexander Broadhead, Thomas O Schrader, Yifeng Xiong, Jill Baccei, Ari J

Presented at Neuroscience 2019

October 19, 2019

The muscarinic M1 antagonist PIPE-359 demonstrates remyelination in vivo through visual evoked potential (VEP) and electron microscopy (EM) of mice with experimental autoimmune encephalitis (EAE)

Geraldine C Edu, Karin J Stebbins, Alexander R Broadhead, Michael M Poon, Ariana O Lorenzana, Thomas Schrader, Yifeng Xiong, Jill Baccei, Ari J Green, Jonah R Chan, and Daniel S Lorrain

Presented at Neuroscience 2019